Established Biologics Do Not Require Name Change, AbbVie Says

Company objects to FDA's plans to retrospectively adopt suffix-based nomenclature for existing biologic products; says resulting confusion, logistical challenges and burdens outweigh FDA's 'not compelling' rationale about perceived inferiority of biosimilars due to different naming conventions.